Genmab A/SNASDAQ:GMAB
- LAST PRICE25.1500
- TODAY'S CHANGE (%)0.2500 (1.0040%)
- Bid / Lots25.2000/ 1
- Ask / Lots26.0000/ 1
- Open / Previous Close25.1000 / 24.9000
- Day Range
- 52 Week Range
- Volume236,621
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GMAB |
|---|---|---|
| 09:32 ET | 9057 | 25.11 |
| 09:34 ET | 508 | 25.121 |
| 09:36 ET | 4842 | 25.11 |
| 09:38 ET | 1782 | 25.16 |
| 09:39 ET | 400 | 25.1442 |
| 09:41 ET | 1550 | 25.19 |
| 09:43 ET | 621 | 25.21 |
| 09:45 ET | 623 | 25.17 |
| 09:48 ET | 400 | 25.17 |
| 09:50 ET | 2644 | 25.17 |
| 09:52 ET | 100 | 25.17 |
| 09:54 ET | 800 | 25.17 |
| 09:56 ET | 1700 | 25.16 |
| 09:57 ET | 200 | 25.18 |
| 09:59 ET | 1340 | 25.19 |
| 10:01 ET | 2732 | 25.21 |
| 10:03 ET | 2233 | 25.14 |
| 10:06 ET | 4048 | 25.14 |
| 10:08 ET | 6995 | 25.17 |
| 10:10 ET | 2687 | 25.17 |
| 10:12 ET | 4391 | 25.18 |
| 10:14 ET | 300 | 25.17 |
| 10:15 ET | 107 | 25.1602 |
| 10:17 ET | 800 | 25.2 |
| 10:19 ET | 7656 | 25.17 |
| 10:21 ET | 8666 | 25.145 |
| 10:26 ET | 5759 | 25.19 |
| 10:28 ET | 700 | 25.14 |
| 10:30 ET | 1124 | 25.15 |
| 10:32 ET | 400 | 25.17 |
| 10:33 ET | 1158 | 25.2 |
| 10:35 ET | 1000 | 25.23 |
| 10:37 ET | 2300 | 25.21 |
| 10:39 ET | 5520 | 25.22 |
| 10:42 ET | 1300 | 25.21 |
| 10:44 ET | 3736 | 25.19 |
| 10:46 ET | 1800 | 25.22 |
| 10:48 ET | 400 | 25.21 |
| 10:50 ET | 1000 | 25.25 |
| 10:51 ET | 1038 | 25.23 |
| 10:53 ET | 3457 | 25.25 |
| 10:55 ET | 5624 | 25.24 |
| 10:57 ET | 5854 | 25.2 |
| 11:00 ET | 9916 | 25.24 |
| 11:02 ET | 200 | 25.23 |
| 11:04 ET | 200 | 25.2 |
| 11:06 ET | 587 | 25.2 |
| 11:08 ET | 700 | 25.19 |
| 11:09 ET | 900 | 25.18 |
| 11:13 ET | 200 | 25.195 |
| 11:15 ET | 100 | 25.19 |
| 11:18 ET | 600 | 25.17 |
| 11:20 ET | 400 | 25.17 |
| 11:22 ET | 1216 | 25.185 |
| 11:24 ET | 706 | 25.19 |
| 11:26 ET | 100 | 25.18 |
| 11:27 ET | 507 | 25.18 |
| 11:29 ET | 220 | 25.165 |
| 11:31 ET | 935 | 25.15 |
| 11:36 ET | 3116 | 25.15 |
| 11:38 ET | 1749 | 25.16 |
| 11:40 ET | 100 | 25.165 |
| 11:42 ET | 586 | 25.19 |
| 11:44 ET | 1300 | 25.2 |
| 11:45 ET | 805 | 25.1608 |
| 11:49 ET | 317 | 25.17 |
| 11:51 ET | 775 | 25.18 |
| 11:54 ET | 400 | 25.19 |
| 11:56 ET | 500 | 25.17 |
| 11:58 ET | 422 | 25.17 |
| 12:00 ET | 831 | 25.15 |
| 12:02 ET | 2111 | 25.14 |
| 12:03 ET | 1692 | 25.15 |
| 12:05 ET | 836 | 25.16 |
| 12:07 ET | 125 | 25.16 |
| 12:09 ET | 1753 | 25.16 |
| 12:12 ET | 348 | 25.1622 |
| 12:14 ET | 977 | 25.16 |
| 12:16 ET | 880 | 25.17 |
| 12:18 ET | 813 | 25.15 |
| 12:20 ET | 924 | 25.16 |
| 12:21 ET | 600 | 25.17 |
| 12:27 ET | 971 | 25.145 |
| 12:30 ET | 1659 | 25.15 |
| 12:32 ET | 700 | 25.166 |
| 12:34 ET | 406 | 25.17 |
| 12:36 ET | 517 | 25.16 |
| 12:38 ET | 1952 | 25.17 |
| 12:39 ET | 1750 | 25.16 |
| 12:43 ET | 542 | 25.14 |
| 12:45 ET | 1700 | 25.14 |
| 12:48 ET | 1697 | 25.125 |
| 12:50 ET | 487 | 25.12 |
| 12:52 ET | 718 | 25.135 |
| 12:54 ET | 700 | 25.145 |
| 12:56 ET | 1750 | 25.15 |
| 12:57 ET | 2949 | 25.16 |
| 12:59 ET | 6312 | 25.15 |
Jun 28, 2024
Epcoritamab (TEPKINLY(R) ) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma, from 2:00AM ET on Friday Jun 28, 2024 by Dow Jones
2:00AM ET on Friday Jun 28, 2024 by Dow JonesEpcoritamab (TEPKINLY(R)) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma, from 2:00AM ET on Friday Jun 28, 2024 by Dow Jones
2:00AM ET on Friday Jun 28, 2024 by Dow Jones
Jun 27, 2024
DJ Genmab Is Maintained at Buy by BTIG, from 8:11AM ET on Thursday Jun 27, 2024 by Dow Jones
8:11AM ET on Thursday Jun 27, 2024 by Dow JonesDJ Genmab Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 6:41AM ET on Thursday Jun 27, 2024 by Dow Jones
6:41AM ET on Thursday Jun 27, 2024 by Dow Jones
Jun 26, 2024
DJ AbbVie Gets New FDA Accelerated Approval for Epkinly, from 7:35PM ET on Wednesday Jun 26, 2024 by Dow Jones
7:35PM ET on Wednesday Jun 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Genmab A/S | 16.6B | 21.0x | +22.71% |
Beam Therapeutics Inc | 1.9B | -13.5x | --- |
Galapagos NV | 1.6B | 49.5x | --- |
Denali Therapeutics Inc | 3.0B | -22.0x | --- |
ADMA Biologics Inc | 2.6B | -549.5x | --- |
Veracyte Inc | 1.6B | -23.0x | --- |
Company Information
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Contact Information
- Headquarters
- Carl Jacobsens Vej 30KOEBENHAVN V, Denmark 2500
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Deirdre Connelly
- President, Chief Executive Officer
- Jan Van De Winkel
- Independent Deputy Chairman of the Board
- Pernille Erenbjerg
- Chief Financial Officer, Executive Vice President
- Anthony Pagano
- Chief Operating Officer, Executive Vice President
- Anthony Mancini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.6B |
|---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 661.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $1.20 |
Book Value | $7.00 |
P/E Ratio | 21.0x |
Price/Sales (TTM) | 6.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | 32.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
